OA01178A - Process for preparing 1,1-dioxides of 3,4-sulfamyl-1,2,4-dihydro, benzothiadiazine. - Google Patents

Process for preparing 1,1-dioxides of 3,4-sulfamyl-1,2,4-dihydro, benzothiadiazine.

Info

Publication number
OA01178A
OA01178A OA51359A OA51359A OA01178A OA 01178 A OA01178 A OA 01178A OA 51359 A OA51359 A OA 51359A OA 51359 A OA51359 A OA 51359A OA 01178 A OA01178 A OA 01178A
Authority
OA
OAPI
Prior art keywords
benzothiadiazine
sulfamyl
dioxides
dihydro
preparing
Prior art date
Application number
OA51359A
Other languages
French (fr)
Original Assignee
Ciba Geigy
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Ciba Geigy filed Critical Ciba Geigy
Publication of OA01178A publication Critical patent/OA01178A/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D285/00—Heterocyclic compounds containing rings having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by groups C07D275/00 - C07D283/00
    • C07D285/15—Six-membered rings
    • C07D285/16—Thiadiazines; Hydrogenated thiadiazines
    • C07D285/18—1,2,4-Thiadiazines; Hydrogenated 1,2,4-thiadiazines
    • C07D285/20—1,2,4-Thiadiazines; Hydrogenated 1,2,4-thiadiazines condensed with carbocyclic rings or ring systems
    • C07D285/22—1,2,4-Thiadiazines; Hydrogenated 1,2,4-thiadiazines condensed with carbocyclic rings or ring systems condensed with one six-membered ring
    • C07D285/24—1,2,4-Thiadiazines; Hydrogenated 1,2,4-thiadiazines condensed with carbocyclic rings or ring systems condensed with one six-membered ring with oxygen atoms directly attached to the ring sulfur atom
    • C07D285/26—1,2,4-Thiadiazines; Hydrogenated 1,2,4-thiadiazines condensed with carbocyclic rings or ring systems condensed with one six-membered ring with oxygen atoms directly attached to the ring sulfur atom substituted in position 6 or 7 by sulfamoyl or substituted sulfamoyl radicals
    • C07D285/28—1,2,4-Thiadiazines; Hydrogenated 1,2,4-thiadiazines condensed with carbocyclic rings or ring systems condensed with one six-membered ring with oxygen atoms directly attached to the ring sulfur atom substituted in position 6 or 7 by sulfamoyl or substituted sulfamoyl radicals with only hydrogen atoms or radicals containing only hydrogen and carbon atoms, directly attached in position 3
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D285/00—Heterocyclic compounds containing rings having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by groups C07D275/00 - C07D283/00
    • C07D285/15—Six-membered rings
    • C07D285/16—Thiadiazines; Hydrogenated thiadiazines
    • C07D285/18—1,2,4-Thiadiazines; Hydrogenated 1,2,4-thiadiazines
    • C07D285/20—1,2,4-Thiadiazines; Hydrogenated 1,2,4-thiadiazines condensed with carbocyclic rings or ring systems
    • C07D285/22—1,2,4-Thiadiazines; Hydrogenated 1,2,4-thiadiazines condensed with carbocyclic rings or ring systems condensed with one six-membered ring
    • C07D285/24—1,2,4-Thiadiazines; Hydrogenated 1,2,4-thiadiazines condensed with carbocyclic rings or ring systems condensed with one six-membered ring with oxygen atoms directly attached to the ring sulfur atom
    • C07D285/26—1,2,4-Thiadiazines; Hydrogenated 1,2,4-thiadiazines condensed with carbocyclic rings or ring systems condensed with one six-membered ring with oxygen atoms directly attached to the ring sulfur atom substituted in position 6 or 7 by sulfamoyl or substituted sulfamoyl radicals
    • C07D285/30—1,2,4-Thiadiazines; Hydrogenated 1,2,4-thiadiazines condensed with carbocyclic rings or ring systems condensed with one six-membered ring with oxygen atoms directly attached to the ring sulfur atom substituted in position 6 or 7 by sulfamoyl or substituted sulfamoyl radicals with hydrocarbon radicals, substituted by hetero atoms, attached in position 3
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
    • C07D417/04—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
    • C07D417/06—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Nitrogen- Or Sulfur-Containing Heterocyclic Ring Compounds With Rings Of Six Or More Members (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
OA51359A 1958-03-03 1964-12-31 Process for preparing 1,1-dioxides of 3,4-sulfamyl-1,2,4-dihydro, benzothiadiazine. OA01178A (en)

Applications Claiming Priority (10)

Application Number Priority Date Filing Date Title
US71845258A 1958-03-03 1958-03-03
US72724258A 1958-04-09 1958-04-09
US74058258A 1958-06-09 1958-06-09
US75162058A 1958-07-29 1958-07-29
US76448258A 1958-09-29 1958-09-29
DEC0028408 1959-02-27
DEC0024176 1959-02-27
DEC0028409 1959-02-27
DEC0024178 1959-02-27
DEC0024177 1959-02-27

Publications (1)

Publication Number Publication Date
OA01178A true OA01178A (en) 1969-01-25

Family

ID=27579177

Family Applications (2)

Application Number Title Priority Date Filing Date
OA51359A OA01178A (en) 1958-03-03 1964-12-31 Process for preparing 1,1-dioxides of 3,4-sulfamyl-1,2,4-dihydro, benzothiadiazine.
OA52080A OA03826A (en) 1958-03-03 1965-06-29 Process for the preparation of a new heterocyclic compound.

Family Applications After (1)

Application Number Title Priority Date Filing Date
OA52080A OA03826A (en) 1958-03-03 1965-06-29 Process for the preparation of a new heterocyclic compound.

Country Status (6)

Country Link
CH (4) CH371454A (en)
DE (4) DE1445574A1 (en)
FR (2) FR1217929A (en)
GB (1) GB861367A (en)
MY (1) MY6200051A (en)
OA (2) OA01178A (en)

Families Citing this family (32)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3200117A (en) * 1962-10-03 1965-08-10 Hoffmann La Roche Derivatives of 1, 2, 4-benzothiadiazine-7-sulfonamide-1, 1-dioxide
DE2642140C2 (en) * 1976-09-20 1982-10-28 Degussa Ag, 6000 Frankfurt Process for the production of benzoyl cyanide
DE8700284U1 (en) * 1987-01-07 1987-04-30 Ernst Reiner GmbH & Co KG, 7743 Furtwangen Post date stamp
CN1293665A (en) * 1998-02-18 2001-05-02 神经研究公司 New compounds and their use as positive AMPA receptor modulators
US6943159B1 (en) 1998-02-18 2005-09-13 Neurosearch A/S Compounds and their use as positive AMPA receptor modulators
US6982251B2 (en) 2000-12-20 2006-01-03 Schering Corporation Substituted 2-azetidinones useful as hypocholesterolemic agents
US7071181B2 (en) 2001-01-26 2006-07-04 Schering Corporation Methods and therapeutic combinations for the treatment of diabetes using sterol absorption inhibitors
DK1355644T3 (en) 2001-01-26 2006-10-23 Schering Corp Use of substituted azetidinone compounds for the treatment of sitosterolemia
HU230253B1 (en) 2001-01-26 2015-11-30 Merck Sharp & Dohme Corp Combinations of peroxisome proliferator-activated receptor (ppar) activator(s) and sterol absorption inhibitor(s) and their use in the treatment of vascular indications
US7053080B2 (en) 2001-09-21 2006-05-30 Schering Corporation Methods and therapeutic combinations for the treatment of obesity using sterol absorption inhibitors
JP2005504091A (en) 2001-09-21 2005-02-10 シェーリング　コーポレイション Treatment of xanthomas with azetidinone as a sterol absorption inhibitor
US7056906B2 (en) 2001-09-21 2006-06-06 Schering Corporation Combinations of hormone replacement therapy composition(s) and sterol absorption inhibitor(s) and treatments for vascular conditions in post-menopausal women
AU2003250483A1 (en) 2002-08-19 2004-03-11 Pfizer Products Inc. Combination therapy for hyperproliferative diseases
WO2004043457A1 (en) 2002-11-06 2004-05-27 Schering Corporation Cholesterol absorptions inhibitors for the treatment of autoimmune disorders
US7459442B2 (en) 2003-03-07 2008-12-02 Schering Corporation Substituted azetidinone compounds, processes for preparing the same, formulations and uses thereof
CA2517571C (en) 2003-03-07 2011-07-05 Schering Corporation Substituted azetidinone compounds, processes for preparing the same, formulations and uses thereof
JP2006519869A (en) 2003-03-07 2006-08-31 シェーリング　コーポレイション Substituted azetidinone compounds, processes for preparing substituted azetidinone compounds, their formulations and uses
JP4589919B2 (en) 2003-03-07 2010-12-01 シェーリング コーポレイション Substituted azetidinone compounds, their formulations and uses for the treatment of hypercholesterolemia
US7741317B2 (en) 2005-10-21 2010-06-22 Bristol-Myers Squibb Company LXR modulators
US7888376B2 (en) 2005-11-23 2011-02-15 Bristol-Myers Squibb Company Heterocyclic CETP inhibitors
CN101663262B (en) 2006-12-01 2014-03-26 百时美施贵宝公司 N-(3-benzyl)-2,2-(diphenyl)-propan-1amine derivatives as CETP inhibitors for the treatment of atherosclerosis and cardiovascular diseases
MX354786B (en) 2007-06-04 2018-03-21 Synergy Pharmaceuticals Inc AGONISTS OF GUANYLATE CYCLASE USEFUL FOR THE TREATMENT OF GASTROINTESTINAL DISORDERS, INFLAMMATION, CANCER and OTHER DISORDERS.
US8969514B2 (en) 2007-06-04 2015-03-03 Synergy Pharmaceuticals, Inc. Agonists of guanylate cyclase useful for the treatment of hypercholesterolemia, atherosclerosis, coronary heart disease, gallstone, obesity and other cardiovascular diseases
ES2522968T3 (en) 2008-06-04 2014-11-19 Synergy Pharmaceuticals Inc. Guanylate cyclase agonists useful for the treatment of gastrointestinal disorders, inflammation, cancer and other disorders
AU2009270833B2 (en) 2008-07-16 2015-02-19 Bausch Health Ireland Limited Agonists of guanylate cyclase useful for the treatment of gastrointestinal, inflammation, cancer and other disorders
US9616097B2 (en) 2010-09-15 2017-04-11 Synergy Pharmaceuticals, Inc. Formulations of guanylate cyclase C agonists and methods of use
AU2014235215A1 (en) 2013-03-15 2015-10-01 Synergy Pharmaceuticals Inc. Agonists of guanylate cyclase and their uses
AU2014235209B2 (en) 2013-03-15 2018-06-14 Bausch Health Ireland Limited Guanylate cyclase receptor agonists combined with other drugs
EP2986599A1 (en) 2013-04-17 2016-02-24 Pfizer Inc. N-piperidin-3-ylbenzamide derivatives for treating cardiovascular diseases
BR112015030326A2 (en) 2013-06-05 2017-08-29 Synergy Pharmaceuticals Inc ULTRAPURE GUANYLATE CYCLASE C AGONISTS, METHOD OF MANUFACTURING AND USING THEM
WO2016055901A1 (en) 2014-10-08 2016-04-14 Pfizer Inc. Substituted amide compounds
BR112021013807A2 (en) 2019-01-18 2021-11-30 Astrazeneca Ab pcsk9 inhibitors and their methods of use

Also Published As

Publication number Publication date
CH387642A (en) 1965-02-15
DE1445007A1 (en) 1968-10-24
CH376514A (en) 1964-04-15
CH371454A (en) 1963-08-31
FR1217929A (en) 1960-05-06
GB861367A (en) 1961-02-22
DE1445006B2 (en) 1975-05-07
DE1445008A1 (en) 1968-10-24
DE1112079B (en) 1961-08-03
OA03826A (en) 1971-12-24
DE1445006A1 (en) 1968-10-24
FR1264468A (en) 1961-06-23
MY6200051A (en) 1962-12-31
DE1445574A1 (en) 1969-01-16
CH377365A (en) 1964-05-15
DE1445005A1 (en) 1968-10-24

Similar Documents

Publication Publication Date Title
OA01178A (en) Process for preparing 1,1-dioxides of 3,4-sulfamyl-1,2,4-dihydro, benzothiadiazine.
OA01196A (en) Process for the preparation of derivatives of the 1,1-dioxide of 3,4-dihydro-1,2,4-benzothiadiazine.
BE576304A (en) Process for preparing 1,1-dioxides of sulfamyl-3,4-dihydro -1,2,4-benzothiadiazine
BE575758A (en) Process for the preparation of substituted benzothiadiazine bioxides.
FR1224766A (en) Process for preparing 1,2,4-benzothiadiazine-1,1-dioxides
FR1271046A (en) Process for preparing 1, 1-dioxides of sulfamyl-3, 4-dihydro-1, 2, 4-benzothiadiazine
BE578374A (en) Process for preparing 6-chloro-7-sulfamyl-3,4-dihydro-1,2,4-benzothiadaizine-1,1-dioxide.
FR1481002A (en) Process for the preparation of 3, 4-dihydro-1, 2. 4-benzothiadiazine-1, 1-dioxides
FR1393951A (en) Process for the preparation of compounds of the 3-oxo-3, 4-dihydro-1, 2, 4-benzothiadiazine-1, 1-dioxide type
FR1341458A (en) Process for preparing 6-chloro-7-sulfamyl-3, 4-dihydro-1, 2, 4-benzothiadiazine-1, 1-dioxide
OA01179A (en) Process for the preparation of derivatives of the 1,1-dioxide of 3,4-dihydro-1,2,4, benzothiadiazine.
BE617986A (en) Process for the preparation of 3-oxo-3,4-dihydro-1,2,4-benzothiadiazine-1,1-dioxides substituted in position 2
BE591152A (en) Process for preparing 3,4-dihydro-1,2,4-benzothiadiazine 1,1-dioxide derivatives
FR1264879A (en) Process for the manufacture of 3, 4-dihydro-1, 2, 4-benzothiadiazine-1, 1-dioxides
OA01373A (en) Process for the preparation of sulfonylureas.
DK126117B (en) Process for the preparation of 1,2,4-benzothiadiazine-1,1-dioxide compounds.
FR1272913A (en) Process for the preparation of 5-alkyl-2-p-halogenobenzenesulfonamido-1, 3, 4-thiadiazoles
BE597435A (en) Process for the preparation of derivatives of the 1,1-dioxide of 3,4-dihydro-1,2,4-benzo-thiadiazine.
FR1298925A (en) Process for preparing 3,4-dihydro-1,2,4-benzothiadiazine 1,1-dioxide derivatives
FR1337762A (en) Process for the preparation of 3, 4-dihydro-1, 2, 4-benzothiadiazine-1, 1-substituted dioxides
BE583907A (en) Process for the preparation of sulfamyl-pyrido [2,3-e] -1,2,4-thiadiazines 1,1-dioxides
BE588339A (en) Process for the preparation of a derivative of 3,4-dihydro-1,2,4-benzothiadiazine 1,1-dioxide
BE583943A (en) Process for the preparation of sulfamyl-3,4-dihydro-pyrido-1,2,4-thiadiazines 1,1-dioxides
FR1283826A (en) Process for the preparation of 1, 1-dioxide derivatives of 3, 4-dihydro-1, 2, 4-benzothiadiazine
BE581588A (en) 6-trifluoromethyl-7-sulfamyl-3,4-dihydro-1,2,4-benzothiadiazine-1,1-dioxides and process for their preparation.